Towa Pharmaceutical Co., Ltd. (TYO:4553)

Towa Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	45,306	45,471	29,650	24,257	32,830
Cash & Short-Term Investments	45,306	45,471	29,650	24,257	32,830
Cash Growth	-0.36%	53.36%	22.23%	-26.11%	43.27%
Receivables	74,002	71,631	71,657	54,392	50,748
Inventory	123,425	108,287	101,072	92,927	72,701
Other Current Assets	24,610	21,917	15,339	11,414	10,585
Total Current Assets	267,343	247,306	217,718	182,990	166,864
Property, Plant & Equipment	170,643	168,423	153,642	127,004	100,857
Long-Term Investments	4,486	3,213	3,006	3,104	3,035
Goodwill	9,468	28,115	32,568	34,613	44,647
Other Intangible Assets	17,212	17,727	18,018	18,332	9,455
Long-Term Deferred Tax Assets	6,136	6,037	5,699	5,303	5,075
Other Long-Term Assets	2	2	2	1	2
Total Assets	475,290	470,823	430,653	371,347	329,935

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	33,343	30,041	26,372	36,070	29,076
Accrued Expenses	97	112	96	117	108
Short-Term Debt	9,317	10,057	6,927	15,224	52,762
Current Portion of Long-Term Debt	21,772	18,023	10,120	7,527	12,172
Current Portion of Leases	1,699	1,383	-	-	-
Current Income Taxes Payable	22,056	20,334	23,911	14,012	15,536
Other Current Liabilities	8,583	7,989	12,692	5,579	5,419
Total Current Liabilities	96,867	87,939	80,118	78,529	115,073
Long-Term Debt	183,335	195,077	189,124	150,314	79,194
Long-Term Leases	12,829	11,801	-	-	-
Pension & Post-Retirement Benefits	132	141	220	322	547
Other Long-Term Liabilities	4,024	4,241	5,299	5,288	2,952
Total Liabilities	297,187	299,199	274,761	234,453	197,766

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	4,717	4,717	4,717	4,717	4,717
Additional Paid-In Capital	7,842	7,841	7,838	7,837	7,837
Retained Earnings	151,815	150,502	134,452	121,232	122,131
Treasury Stock	-5,584	-5,586	-5,606	-5,608	-5,608
Comprehensive Income & Other	19,313	14,150	14,491	8,716	3,092
Shareholders' Equity	178,103	171,624	155,892	136,894	132,169
Total Liabilities & Equity	475,290	470,823	430,653	371,347	329,935

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	228,952	236,341	206,171	173,065	144,128
Net Cash (Debt)	-183,646	-190,870	-176,521	-148,808	-111,298
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-3730.55	-3877.50	-3586.33	-3023.21	-2211.60
Filing Date Shares Outstanding	49.23	49.23	49.22	49.22	49.22
Total Common Shares Outstanding	49.23	49.23	49.22	49.22	49.22
Working Capital	170,476	159,367	137,600	104,461	51,791
Book Value Per Share	3617.93	3486.37	3167.24	2781.16	2685.17
Tangible Book Value	151,423	125,782	105,306	83,949	78,067
Tangible Book Value Per Share	3075.96	2555.14	2139.49	1705.52	1586.02

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error